Complete Scientific Guide to Iron Bisglycinate

1. Executive Summary / Quick Facts

Iron bisglycinate, also called ferrous bisglycinate, ferrous bisglycinate chelate or iron glycinate, is a mineral form of iron in which one ferrous iron ion (Fe2+) is bound to two molecules of the amino acid glycine. It is used to prevent and treat iron deficiency, to support iron status during pregnancy and childhood, and to fortify foods and beverages. Its reputation rests on two practical advantages: it is absorbed well even from meals that contain absorption inhibitors such as phytate, and it is generally easier on the stomach than conventional ferrous salts such as ferrous sulfate.

This guide reviews the chemistry, manufacturing, absorption, clinical evidence, dosing, safety, quality control and regulation of iron bisglycinate. It separates what is well supported by controlled human trials from what is plausible but unproven, and it flags where marketing claims go further than the science.

Quick facts 

Attribute	Detail
Ingredient	Iron (mineral form)
Common names	Iron bisglycinate, ferrous bisglycinate, ferrous bisglycinate chelate, iron glycinate, bis(glycinato)iron(II)
Chemical class	Metal–amino acid chelate (coordination complex)
Molecular formula	C4H8FeN2O4 (anhydrous)
Molecular weight	About 204 g/mol
Theoretical iron content	About 27% by weight (pure anhydrous); commercial grades are commonly standardized to about 20% elemental iron
Iron oxidation state	Ferrous (Fe2+)
Source	Synthetic; made from a ferrous iron source and glycine
Main uses	Iron deficiency, iron deficiency anemia, prenatal nutrition, pediatric supplementation, food fortification
Typical study doses	About 15 to 60 mg elemental iron per day in adults; weight-based dosing in children
US RDA (adults)	8 mg/day for men; 18 mg/day for women aged 19–50; 27 mg/day in pregnancy
Tolerable upper intake level	45 mg/day elemental iron for adults (supplements and food combined)
Evidence strength	Moderate for correcting iron deficiency and anemia; moderate for better GI tolerability; limited for most other outcomes
Key cautions	Not for people with hemochromatosis or iron overload; accidental overdose is dangerous in children; many drug interactions

 

Key Takeaways

•       Same mineral, different carrier. The therapeutic agent is still iron. The glycine ligand changes how the iron behaves in the gut, not what iron does in the body.

•       Strongest evidence: it raises hemoglobin and ferritin in iron-deficient people, and in pregnancy a lower dose has matched a higher dose of ferrous sulfate in randomized trials.

•       Tolerability: several trials and a recent meta-analysis point to fewer gastrointestinal complaints than with ferrous sulfate, although study quality varies.

•       Bioavailability: advantages are largest when inhibitors such as phytate, polyphenols or milk are present. With no inhibitors, absorption is broadly similar to ferrous sulfate.

•       Dose by elemental iron, not by compound weight. Always read the Supplement Facts panel for the elemental iron amount.

•       Test before you supplement. Iron should be taken when deficiency is confirmed or strongly suspected, because excess iron is not harmless.

2. Ingredient Definition and Identity

Iron bisglycinate is a defined chemical compound, not a plant extract or a blend. The name describes its structure. "Bis" means two, "glycinate" refers to the glycine anion, and the iron at the center is in the ferrous state. In a pure molecule, the ratio of iron to glycine is 1 to 2.

Names You Will See on Labels

•       Ferrous bisglycinate and ferrous bisglycinate chelate: the most technically precise names.

•       Iron bisglycinate and iron bisglycinate chelate: the most common supplement-facts wording.

•       Iron glycinate: a looser term. It is sometimes used for the true bisglycinate chelate and sometimes for physical mixtures or other glycine-iron products, so it deserves a closer look.

•       Ferrochel: a registered trademark of Albion Laboratories (part of Balchem) for its ferrous bisglycinate chelate. Seeing a trademark on a label tells you the raw material source, which can be useful for quality purposes.

What It Is Not

It is not heme iron, which comes from animal hemoglobin and myoglobin and is absorbed by a separate pathway. It is not ferric (Fe3+) iron, although a related compound, ferric trisglycinate, has been studied. It is not a food-sourced iron, and it is not a "natural" extract. It is a manufactured mineral ingredient that is nutritionally identical at the elemental level to the iron found in food.

Reading the Label Correctly

In the United States and many other markets, the Supplement Facts panel shows the amount of elemental iron followed by the source in brackets, for example "Iron (as ferrous bisglycinate chelate) 25 mg." This means the capsule delivers 25 mg of iron, not 25 mg of the compound. Because pure iron bisglycinate is roughly 20 to 27% iron, a capsule delivering 25 mg of iron contains approximately 90 to 125 mg of the compound. Comparing products by milligrams of compound alone is a common mistake.

3. Botanical / Chemical Classification

Because iron bisglycinate is a mineral compound, there is no botanical classification. There is no genus, species, plant part or growing region. The relevant classification is chemical and nutritional.

Chemical Classification

•       Kingdom of compounds: inorganic–organic hybrid; a coordination complex.

•       Class: metal–amino acid chelate.

•       Metal center: iron(II), also written Fe2+ or ferrous iron.

•       Ligands: two glycine molecules, each bonding to the iron through the amino nitrogen and a carboxylate oxygen.

•       Overall charge: neutral.

•       Commonly cited CAS number: 20150-34-9.

Why It Is Called a Chelate

The word chelate comes from the Greek word for claw (chele), a term introduced by the chemists Gilbert Morgan and Harry Drew in 1920. A chelate forms when a single ligand grips a metal ion at two or more points, closing a ring. In iron bisglycinate each glycine attaches through two atoms, so the molecule contains two five-membered rings. This ring structure is the reason the complex is relatively stable across the pH range found in the stomach and upper intestine.

The Association of American Feed Control Officials (AAFCO) provides a widely used regulatory definition of an amino acid chelate: a product formed by the reaction of a metal ion from a soluble metal salt with amino acids, at a molar ratio of one mole of metal to one to three (preferably two) moles of amino acids, forming covalent coordinate bonds, with a hydrolyzed amino acid average weight of about 150 daltons and a finished molecular weight not exceeding 800 daltons. Iron bisglycinate fits this definition at a 1 to 2 ratio.

Comparison With Other Iron Forms

Iron form	Approx. iron by weight	Notes
Ferrous sulfate (heptahydrate)	About 20%	Reference standard in trials; inexpensive; most GI side effects reported
Ferrous sulfate (dried)	About 30–37%	Common in tablets; same absorption behavior as heptahydrate
Ferrous fumarate	About 33%	Poorly water soluble; widely used in fortification
Ferrous gluconate	About 12%	Lower iron per tablet; milder reputation
Ferrous bisglycinate (chelate)	About 20% (commercial)	Amino acid chelate; good absorption with inhibitors; gentler on the gut
Carbonyl iron	About 98–99%	Slow-dissolving elemental iron powder; low acute toxicity profile
Polysaccharide-iron complex	Varies by product	Ferric iron bound to a carbohydrate; less evidence than ferrous salts
Ferric pyrophosphate	About 25%	Low reactivity in foods; poorly soluble
Sodium iron EDTA	About 13%	Used in fortification of phytate-rich foods
Heme iron polypeptide	Low percentage	Animal-derived; absorbed through the heme pathway

 

4. Origin, Cultivation and Source

Iron bisglycinate is not cultivated, harvested or extracted from a natural organism. It is produced industrially from two raw materials: an iron source and glycine. For this reason, the question that matters is not "where is it grown" but "how pure are the inputs and how well is the process controlled."

The Iron Source

Manufacturers typically start with a ferrous salt such as ferrous sulfate, ferrous carbonate or ferrous fumarate, or with reduced metallic iron. These originate from processed iron ore or from by-products of steel and titanium dioxide production. Iron is the fourth most abundant element in the Earth's crust, so supply is never an issue. The concerns are trace contaminants carried over from industrial sources, such as lead, arsenic, cadmium and mercury, which is why heavy-metal testing of the finished ingredient is essential.

The Glycine Source

Glycine is the simplest amino acid. It is produced on a commercial scale mainly by chemical synthesis, for example from chloroacetic acid and ammonia, or by the Strecker route, and in some cases by fermentation or protein hydrolysis. Most food-grade and pharmaceutical-grade glycine is synthetic, which is why iron bisglycinate is generally suitable for vegetarians and vegans. Brands should still confirm this with the supplier, because a small number of amino acids on the market are animal-derived.

Geography and Supply Chain

Iron bisglycinate is manufactured in North America, Europe and Asia. Branded and patented grades are made under controlled processes with a defined chelation percentage, while generic grades vary more. Buyers should ask for a certificate of analysis for each batch, supplier audit records, and evidence of GMP compliance.

Context: Dietary Iron Sources

Supplements sit alongside diet. Heme iron from red meat, poultry and fish is absorbed at roughly 15 to 35%. Non-heme iron from plants, eggs, dairy and fortified foods is absorbed at roughly 2 to 20%, depending on iron status and meal composition. Iron bisglycinate is a non-heme iron source, but its chelated structure makes it behave differently from simple non-heme salts in the presence of inhibitors.

5. History and Traditional Use

Iron has a longer medical history than almost any other mineral. Ancient Egyptian, Greek, Roman and Indian traditions describe iron or iron-rich preparations for weakness, pallor and exhaustion. The Greek legend of Melampus describes iron rust steeped in wine as a treatment for impotence, and Ayurvedic texts describe processed iron preparations known as Lauha Bhasma. These uses were empirical, and their mechanism was not understood.

Early Scientific Milestones

•       1700s: Vincenzo Menghini demonstrated in 1745 that blood contains iron.

•       1600s–1800s: Thomas Sydenham and later physicians used iron filings in wine for chlorosis, an anemia of young women.

•       1832: Pierre Blaud introduced Blaud's pills, based on ferrous sulfate and potassium carbonate, a landmark in oral iron therapy.

•       1930s–1950s: Ferrous sulfate became the standard oral therapy, and its limits in tolerability were documented.

The Rise of Amino Acid Chelates

The chelation concept came from coordination chemistry in the early 1900s. Applied to nutrition, researchers in the United States, notably at Albion Laboratories in Utah, developed amino acid chelates of minerals in the mid-twentieth century, with the aim of making minerals more absorbable and gentler. Iron bisglycinate emerged as one of the most studied chelates.

The key human research came in the 1990s and 2000s, especially from teams at the Institute of Nutrition and Food Technology (INTA) in Santiago, Chile, including Olivares, Pizarro, Hertrampf and Pineda, with parallel work by Layrisse and colleagues in Venezuela and by Bovell-Benjamin, Viteri and Allen in the United States. These groups used radioisotopes and clinical trials to test whether the chelate resisted inhibitors and whether it corrected anemia in children and pregnant women.

Traditional Use

Iron bisglycinate itself has no traditional use. It is a modern ingredient. Its history is better described as a convergence of long-standing traditional iron therapy and modern chemistry and nutrition science.

6. Modern Nutraceutical Use

Today, iron bisglycinate occupies several roles across supplements, medical nutrition and the food industry.

Dietary Supplements

It is sold as a stand-alone iron capsule or tablet, as a component of prenatal and postnatal multivitamins, in women's health formulas, in liquid drops for infants and toddlers, and in combination products with vitamin C, vitamin B12, folate and copper. Marketing emphasizes "gentle iron," "non-constipating iron" and "high absorption iron." The first two claims have partial support from trials. The third needs context, because absorption depends on iron status and meal composition.

Prenatal and Women's Health

Pregnancy sharply raises iron requirements, and nausea and constipation are already common. Iron bisglycinate is therefore widely used in prenatal products. Women with heavy menstrual bleeding, frequent blood donors and endurance athletes are other common users.

Pediatric Nutrition

Because ferrous sulfate drops are known for metallic taste and tooth staining, iron bisglycinate is used in pediatric formulations, fortified milks, cereals and micronutrient powders. Pediatric use must follow medical guidance because of overdose risk.

Food and Beverage Fortification

Iron bisglycinate is used to fortify dairy products, cereals, beverages and bars. Compared with ferrous sulfate, it tends to cause fewer taste, color and fat-oxidation problems in food, and it is less affected by phytate in cereal-based foods. This makes it attractive where staples are rich in inhibitors.

Plant-Based Diets

People following vegetarian or vegan diets absorb less non-heme iron because of phytates and polyphenols in plant foods. A form that is less sensitive to these inhibitors is therefore of practical interest, although dietary strategies such as combining iron-rich foods with vitamin C remain first-line.

7. Chemical Composition

The composition of iron bisglycinate is simple, and that simplicity is helpful for quality control.

Elemental Composition

Component	Mass contribution	Comment
Iron (Fe)	55.85 g/mol (about 27.4%)	Ferrous state; the nutritionally active mineral
Two glycine units (C2H4NO2 each)	About 148 g/mol (about 72–74%)	Amino acid ligands bound through N and O
Total (anhydrous)	About 204 g/mol	Neutral complex

 

In real products the iron content is lower than the theoretical 27% because of water content, residual process materials and, in some grades, intentional stabilizers. Commercial specifications commonly state a minimum of about 19 to 20% iron.

Coordination Chemistry

Each glycine donates its amino nitrogen and one carboxylate oxygen to the iron center, creating two five-membered heterocyclic rings. The iron is typically six-coordinate in the solid state, with water molecules or additional bridging occupying remaining sites. In solution, stability depends on pH. The chelate is relatively stable in the mildly acidic range encountered in the stomach and small intestine, whereas strong acid or very high pH will progressively release iron.

Physical Properties

•       Appearance: powder, typically pale to olive or brownish-green depending on grade and moisture.

•       Solubility: soluble in water, more so than many iron salts used in fortification.

•       Taste: less metallic and astringent than ferrous sulfate.

•       Oxidation: ferrous iron can oxidize to ferric iron in air and moisture over time, so manufacturers control moisture, use protective packaging and sometimes add antioxidants.

Typical Quality Specifications

Specifications vary by manufacturer, but a pharmaceutical or food-grade specification generally includes assay for iron, ferrous iron percentage, glycine content, chelation percentage, loss on drying, pH, heavy metals (lead, arsenic, cadmium, mercury), microbiological limits and residual solvents if applicable. These parameters are discussed in Section 23.

8. Key Active Compounds

Ferrous Iron (Fe2+)

Iron is the sole active nutrient. It is required for hemoglobin and myoglobin, for cytochromes and iron-sulfur proteins in cellular energy production, for enzymes involved in DNA synthesis and neurotransmitter production, and for immune function. Every effect attributed to iron bisglycinate in the body depends on the iron it delivers.

Glycine

Glycine is a non-essential amino acid involved in collagen, creatine, glutathione and heme synthesis, and it acts as an inhibitory neurotransmitter in the central nervous system. However, the amount delivered by a typical iron bisglycinate dose is small. A capsule containing 25 mg of iron supplies roughly 70 to 90 mg of glycine, compared with about 2 to 3 g of glycine consumed daily in an average diet. The glycine in iron bisglycinate is therefore best viewed as a carrier, not as a separate active ingredient.

The Intact Chelate

Whether the intact chelate itself is a relevant active species is the central scientific question. The evidence suggests that the chelate protects iron from binding to dietary inhibitors during digestion, and that at least some iron enters enterocytes through pathways shared with non-heme iron. These mechanisms are covered in Section 11.

Companion Nutrients

Many iron bisglycinate products are combined with vitamin C, which improves non-heme iron absorption, and with folate and vitamin B12, which support red blood cell formation. Copper and vitamin A also influence iron metabolism. Formulation matters, because high doses of calcium or zinc in the same product can compete with iron absorption.

9. Extraction and Processing

Iron bisglycinate is not extracted. It is synthesized, so the relevant discussion is about process chemistry and quality control.

General Manufacturing Steps

1.    Raw material qualification: the iron source and glycine are tested for identity and purity, including heavy metals.

2.    Chelation reaction: glycine and the ferrous source are reacted in water, at controlled temperature and pH, usually at a 2 to 1 molar ratio of glycine to iron. The reaction displaces the original anion, such as sulfate, carbonate or fumarate, and forms the chelate.

3.    Oxidation control: because Fe2+ readily oxidizes to Fe3+, the process uses limited oxygen exposure, controlled pH and sometimes antioxidants such as ascorbic or citric acid.

4.    Purification and filtration: insoluble residues and by-products are removed. Depending on the route, soluble by-products may be left in the final product or removed.

5.    Concentration and drying: the solution is concentrated and spray-dried or otherwise dried into a stable powder.

6.    Milling, blending and testing: the powder is sized and tested for iron content, ferrous content, chelation percentage, moisture and contaminants.

7.    Packaging: moisture- and oxygen-protective packaging is used to maintain the ferrous state.

Why Process Control Matters

Incomplete reaction yields a product that contains free ferrous salt and free glycine rather than true chelate. Excessive heat, wrong pH or air exposure can increase ferric content or produce discolored material. The performance claims for iron bisglycinate, including resistance to inhibitors and gentleness, apply to the true chelate and not to physical mixtures.

Finished Dosage Form Processing

The powder is encapsulated, tableted, dissolved in liquid vehicles or incorporated into premixes for fortification. Tablets are often coated to mask taste and protect the iron from moisture. Liquid forms often contain acidulants and antioxidants. Gummies are challenging because iron can degrade flavor and color, so gummy iron doses are usually low.

10. Standardization and Potency

Standardizing to Elemental Iron

Potency in iron supplements is expressed as elemental iron per serving. Standardization means that each batch is adjusted, by blending or by selecting raw material lots, to deliver a defined amount of elemental iron. For iron bisglycinate, the raw material is typically specified at a minimum of about 20% iron.

Worked Example

If a manufacturer wants a capsule with 25 mg of elemental iron and uses raw material with a 20% iron assay, the capsule must contain 25 divided by 0.20, or 125 mg of iron bisglycinate. If the raw material assays at 22% iron, the required amount drops to about 114 mg. This is why labels should always state elemental iron and why potency should be verified by testing.

Chelation Percentage and Ferrous Content

Two additional potency-related markers matter specifically for chelates. The first is the percentage of iron actually present as chelate, rather than as free iron salts. The second is the percentage of iron present as ferrous rather than ferric. Higher-quality ingredients publish both values, and independent laboratories can verify them using titration, spectroscopic and chromatographic methods.

Overage and Shelf Life

Manufacturers sometimes add a small overage to ensure the label claim is met through the end of shelf life. Iron is relatively stable compared with vitamins, but oxidation and moisture can alter the ferrous fraction. Good practice includes stability testing at accelerated and real-time conditions and labeling with a defined expiry date.

Potency Versus Bioavailable Potency

Elemental iron content does not equal absorbed iron. Two products with 25 mg of elemental iron can deliver different absorbed amounts depending on the compound, the formulation, meal timing and the user's iron status. This distinction underlies the whole bioavailability discussion that follows.

11. Mechanisms of Action

The Iron Absorption Pathway

To understand what is special about iron bisglycinate, it helps to recall how the body handles ordinary non-heme iron. Dietary ferric iron is reduced to ferrous iron by duodenal cytochrome B (Dcytb) and gastric acid. Ferrous iron is transported into duodenal enterocytes by divalent metal transporter 1 (DMT1). Inside the cell, iron is either stored in ferritin or exported across the basolateral membrane by ferroportin, oxidized by hephaestin and loaded onto transferrin in the blood. The hormone hepcidin, produced by the liver, controls the process by binding ferroportin and causing its degradation. When iron stores are low, hepcidin falls and absorption rises. When stores are high or inflammation is present, hepcidin rises and absorption falls.

Hypothesis 1: Protection From Inhibitors

The most widely accepted explanation for the behavior of iron bisglycinate is protective chelation. Simple ferrous salts dissociate in the stomach and release free Fe2+, which can bind phytate in cereals and legumes, polyphenols in tea, coffee and some vegetables, and calcium and proteins in milk. These complexes are poorly absorbed. Because the iron in bisglycinate is held within a ring structure, it is less available to these binders, so more iron survives to reach the absorptive surface. Human isotope studies in which iron bisglycinate was given with phytate-rich maize or with breakfast meals containing polyphenols are consistent with this idea.

Hypothesis 2: Intact or Partly Intact Uptake

Early authors proposed that the chelate might be absorbed intact through amino acid or small peptide transporters, bypassing DMT1. This idea has intuitive appeal, but the evidence is mixed. A human study by Pizarro and colleagues found that ferrous sulfate reduced the absorption of iron from bisglycinate, which suggests the two forms compete for at least part of the same non-heme iron pathway. Other cell and animal work suggests that iron may be released from the ligand at or near the brush border and then handled like other ferrous iron. The most reasonable current view is that iron bisglycinate is a ferrous iron carrier that protects iron during digestion and then largely enters the normal regulated iron pathway.

Regulation by Iron Status

The key point is that iron bisglycinate does not escape regulation. Studies with radioisotopes show that absorption from iron bisglycinate is higher in people with low iron stores and lower in people with replete stores, just as for ferrous sulfate. This is a safety-relevant finding because it means the body can downregulate absorption when iron is sufficient, although this regulation is not perfect at high doses.

Gastrointestinal Mechanisms of Tolerability

Gastrointestinal side effects of oral iron are thought to arise from unabsorbed iron in the gut lumen, which can irritate the mucosa, generate reactive oxygen species and alter the intestinal microbiota. If more of the iron is absorbed at lower doses, or if the chelate is less irritating, tolerability improves. Both mechanisms are plausible for iron bisglycinate, but direct mechanistic proof in humans is limited.

Downstream Physiological Effects

Once absorbed, iron is incorporated into hemoglobin in developing red blood cells in the bone marrow, into myoglobin in muscle, and into cytochromes and iron-sulfur enzymes. Correcting iron deficiency can improve hemoglobin, oxygen delivery, exercise capacity, cognitive function, thyroid hormone synthesis and immune performance, particularly in people who were deficient to begin with.

12. Pharmacokinetics

Pharmacokinetics of iron differs from that of most drugs because iron is a nutrient that is tightly conserved and cannot be actively excreted.

Absorption

Absorption occurs mainly in the duodenum and proximal jejunum. The fraction absorbed depends strongly on iron status. Iron-deficient adults may absorb 20 to 35% of a dose given under ideal conditions, while iron-replete adults may absorb less than 10%. In isotope studies, absorption from iron bisglycinate has ranged from a few percent from inhibitor-rich meals in replete individuals to considerably higher figures in deficient individuals taking it without inhibitors.

Distribution

Absorbed iron binds to transferrin in plasma and is delivered to the bone marrow, liver, spleen and other tissues through transferrin receptors. About two thirds of body iron, roughly 2.5 to 3 g in an adult, is in hemoglobin. Most of the rest is stored in ferritin and hemosiderin in the liver, spleen and bone marrow.

Time Course

After an oral dose, serum iron typically rises within the first one to three hours and then returns toward baseline. The half-life of plasma iron is short, on the order of one to two hours, because iron is rapidly taken up by tissues. A single dose of oral iron also triggers a rise in hepcidin, which peaks roughly 12 to 24 hours later and suppresses absorption from subsequent doses for up to about 48 hours. This hepcidin response is the physiological basis for alternate-day dosing strategies discussed in Section 18.

Metabolism and Elimination

Iron is not metabolized in the usual sense. If the chelate dissociates, glycine enters the amino acid pool and is used or oxidized normally. Iron is recycled efficiently: macrophages recycle iron from senescent red blood cells and return it to transferrin. Daily losses are about 1 mg in men and postmenopausal women, through shed intestinal cells, skin and urine, and about 1.5 to 2 mg per day on average in menstruating women. Unabsorbed iron is excreted in the feces, which is why stools darken during supplementation.

Parameter	Approximate value or behavior
Site of absorption	Duodenum and proximal jejunum
Fraction absorbed	Roughly 5 to 35%, inversely related to iron stores
Time to peak serum iron	About 1 to 3 hours
Plasma iron half-life	About 1 to 2 hours
Carrier in blood	Transferrin
Hepcidin peak after dose	About 12 to 24 hours; absorption suppressed for up to 48 hours
Main storage forms	Ferritin and hemosiderin
Routes of loss	Cell shedding, bleeding, menstruation; no regulated excretion

 

Human pharmacokinetic data specific to iron bisglycinate are less extensive than the data for ferrous sulfate, and most published work uses isotopes or hematological outcomes rather than full concentration-time curves.

13. Bioavailability

What the Studies Show

Bioavailability is the central claim for iron bisglycinate, and the evidence is more nuanced than marketing suggests. Several human isotope studies are especially informative.

•       Phytate-rich maize: Bovell-Benjamin and colleagues (2000) compared ferrous bisglycinate with ferrous sulfate in whole maize meals, which are high in phytate. Absorption from the bisglycinate was higher than expected from ferrous sulfate in this inhibitor-rich matrix, and absorption was regulated by iron status.

•       Breakfasts with phytate and polyphenols: Layrisse and colleagues (2000) tested breakfasts enriched with iron bisglycinate and found that its bioavailability was less reduced by phytate and polyphenols than that of ferrous sulfate.

•       Milk and ascorbic acid: Olivares and colleagues (1997) found that milk inhibited absorption of iron from the chelate and that ascorbic acid improved it. Inhibitors still matter, even if the chelate resists them better, and vitamin C still helps.

•       Shared pathway: Pizarro and colleagues (2002) showed competition between ferrous sulfate and the chelate, which suggests a shared absorption route rather than a completely separate one.

Relative Bioavailability

Reviews of isotope studies generally conclude that iron bisglycinate is about as well absorbed as ferrous sulfate when meals are low in inhibitors, and about two to four times better absorbed when strong inhibitors such as phytate are present. These are approximate ranges drawn from different study designs, and they should not be treated as fixed constants. Claims that bisglycinate is "ten times more absorbable" than other forms are not supported by controlled human data.

Bioavailability Versus Clinical Effect

Higher absorption in a single-meal isotope study does not automatically translate into better hemoglobin recovery over months. Clinical trials are therefore needed, and these show that lower doses of iron bisglycinate can match higher doses of ferrous sulfate in some populations, particularly pregnancy. Where the sulfate dose is already adequate and well tolerated, the clinical advantage is smaller.

Factors That Change Absorption

Factor	Effect on iron absorption
Low iron stores or anemia	Increases absorption
High hepcidin (inflammation, recent iron dose)	Decreases absorption
Vitamin C	Increases absorption of non-heme iron
Phytate (grains, legumes, nuts)	Decreases absorption; less so for the chelate
Polyphenols (tea, coffee, cocoa, some herbs)	Decrease absorption
Calcium (supplements, dairy)	Decreases absorption in the same meal
Large single doses	Lower fractional absorption per dose
Gastric acid suppression	May reduce absorption of iron salts; effect on the chelate is less certain

 

Many of the key isotope studies on iron bisglycinate were small and some were supported by the raw material manufacturer or conducted by research groups closely associated with its development. This does not invalidate the results, but it argues for more independent replication.

14. Preclinical Evidence Summary

Cell Culture Studies

Caco-2 cell monolayers, a standard model of intestinal absorption, have been used to compare iron uptake from various forms. Results generally show that iron from bisglycinate is taken up by the cells and is influenced by the presence of inhibitors, but findings differ between laboratories and depend on digestion conditions. These models cannot fully replicate gastric digestion, transit or hepcidin signaling.

Animal Studies

Iron-deficient rodent models have been used to compare repletion of hemoglobin and tissue iron after dosing with iron bisglycinate and other iron forms. Many report that iron bisglycinate restores hemoglobin at least as effectively as ferrous sulfate, with some reporting advantages at equal iron doses. Some animal work also suggests lower lipid oxidation in food matrices and in the gut, and less disturbance to intestinal histology, although results are not uniform.

Toxicology

A subchronic rat toxicity study and accompanying safety evaluation by Jeppsen and Borzelleca (1999) found no adverse effects attributable to ferrous bisglycinate at the doses tested, beyond those expected from iron itself. The safety profile of the chelate in animals is consistent with that of other iron compounds, with the limiting factor being total iron load.

Gut Microbiota and Oxidative Stress

Excess unabsorbed iron can alter gut microbial composition, increase pathogenic species and promote intestinal inflammation, as shown in a Kenyan infant trial of iron-containing micronutrient powders (Jaeggi et al., 2015). Whether iron bisglycinate has a smaller effect on the microbiota than ferrous sulfate is plausible, because less iron may reach the colon, but direct comparative data in humans are limited.

Limits of Preclinical Evidence

Animal and cell studies are useful for mechanisms and safety signals, but they have limited power to predict human clinical benefits. Dose, diet, species-specific iron handling and study duration all differ from real-world human use. For that reason, human trials receive greater weight in the evidence grading that follows.

15. Human Clinical Evidence Summary

Pregnancy

Pregnancy has the most persuasive randomized evidence. In a Danish trial, Milman and colleagues (2014) randomized pregnant women to 25 mg of iron as ferrous bisglycinate or 50 mg of iron as ferrous sulfate. After the intervention, hemoglobin and iron status were comparable between groups, with fewer gastrointestinal complaints in the bisglycinate group. This supports the conclusion that a lower dose of the chelate can match a higher dose of ferrous sulfate for prophylaxis. Other trials in pregnancy have reported similar or better hemoglobin responses with the chelate, although designs and populations vary.

Infants and Children

Pineda and Ashmead (2001) reported that ferrous bisglycinate was effective in treating iron deficiency anemia in infants and young children, with improvements in hemoglobin and ferritin. In a randomized trial of Mexican schoolchildren, Duque and colleagues (2014) compared ferrous sulfate and iron bisglycinate and found that both raised ferritin concentrations. The results in children are generally positive but not uniformly superior to ferrous sulfate, and some pediatric studies are small or have methodological limitations.

Adults

Evidence in non-pregnant adults is less extensive. Smaller trials and observational reports describe improvement in hemoglobin and ferritin and fewer side effects with iron bisglycinate than with ferrous sulfate. Adults with iron deficiency without anemia may also experience improvements in fatigue when iron status is corrected. A systematic review of randomized trials in non-anemic iron-deficient adults (Houston et al., 2018) found that iron supplementation, regardless of form, improved fatigue, which suggests that the benefit comes from correcting iron deficiency itself.

Systematic Reviews

A systematic review and meta-analysis by Fischer and colleagues (2023) examined randomized trials of oral ferrous bisglycinate in adults and children. It reported higher hemoglobin concentrations in pregnant women taking ferrous bisglycinate compared with other iron forms, and fewer gastrointestinal adverse events overall, while evidence in other groups was limited and many trials were rated at some risk of bias. This is the best single summary of the current clinical literature, and its cautious conclusions are the right frame for interpreting the field.

Tolerability in Context

A well-known meta-analysis by Tolkien and colleagues (2015) showed that ferrous sulfate causes significantly more gastrointestinal side effects than placebo in adults, which established a baseline problem that alternative iron forms aim to solve. Head-to-head evidence for iron bisglycinate suggests lower rates of nausea, constipation and abdominal pain, but the magnitude varies and blinding is often imperfect.

Fortification Studies

Trials of fortified foods, including milk and cereal products, show that iron bisglycinate can improve iron status in children and women, with organoleptic advantages. Results depend on the food matrix, the iron dose and the background diet.

Other Populations

Evidence in inflammatory bowel disease, chronic kidney disease, bariatric surgery patients and athletes is limited and mostly based on small studies or extrapolation from other iron forms. In these groups, intravenous iron is often preferred when oral iron fails or is not tolerated.

16. Evidence Grading by Outcome

The grades below are an editorial summary, not a formal GRADE assessment. They reflect the number, size, design and independence of studies, consistency of results and directness to the outcome. "Strong" means multiple consistent randomized trials or meta-analyses. "Moderate" means some randomized evidence with limitations. "Limited" means few or small studies. "Insufficient" means too little data to judge.

Outcome	Evidence grade	Rationale
Raises hemoglobin and ferritin in iron deficiency anemia	Moderate to strong	Multiple randomized trials and meta-analysis; same direction as other iron salts
Prevents iron deficiency and anemia in pregnancy at lower elemental dose than ferrous sulfate	Moderate	Randomized trial evidence (for example Milman 2014) and meta-analytic support; more independent replication needed
Fewer gastrointestinal side effects than ferrous sulfate	Moderate	Consistent in several trials; blinding and reporting quality vary
Better absorption than ferrous sulfate in phytate-rich meals	Moderate	Isotope studies; small samples; some industry association
Better absorption than ferrous sulfate in inhibitor-free meals	Weak or none	Studies show similar absorption
Improves iron status in children	Moderate	Positive trials; not consistently superior to ferrous sulfate
Improves fatigue in non-anemic iron deficiency	Moderate (for iron generally)	Evidence derived from iron supplementation overall, not bisglycinate specifically
Lower constipation than other forms	Limited to moderate	Some trial reports; not consistent
Improves athletic performance	Insufficient	Benefit only expected when deficient; no strong bisglycinate-specific data
Improves cognition or mood independent of deficiency	Insufficient	No convincing evidence in iron-replete people
Benefit in iron-replete individuals	None demonstrated	Supplementation is not recommended without need
Gut microbiome advantages over other iron forms	Insufficient	Mechanistic plausibility; little direct human data

 

17. Dosages Used in Studies

Doses should always be understood as elemental iron. The following ranges summarize doses used in studies and recommended by guidelines. They are for information and should not replace medical advice.

Population	Typical dose in studies or guidelines	Notes
Adults, iron deficiency or anemia	About 15 to 60 mg elemental iron per day; sometimes 100 mg per day or alternate-day	Higher doses increase side effects without proportionally higher absorption
Pregnancy (prevention)	25 to 30 mg per day in trials; WHO recommends 30 to 60 mg per day	Individualize based on hemoglobin and ferritin
Pregnancy (treatment of anemia)	Often 60 to 120 mg per day under clinical supervision	Intravenous iron may be considered in selected cases
Infants and children	Weight-based, commonly in the range of a few mg per kg per day under medical supervision	Never self-dose; use pediatric products and measuring devices
Food fortification	Varies by food and program	Designed to meet a fraction of daily needs

 

Reference Intakes

•       US RDA, adults 19 to 50 years: 8 mg/day for men and 18 mg/day for women.

•       US RDA, women 51 years and older: 8 mg/day.

•       US RDA, pregnancy: 27 mg/day; lactation: 9 mg/day for adults.

•       Tolerable upper intake level: 45 mg/day for adults and adolescents 14 years and older, and 40 mg/day for children under 14.

•       Vegetarian requirement: the US Institute of Medicine suggests about 1.8 times the standard requirement because non-heme iron is less bioavailable.

Dose Size and Absorption

The relationship between dose and absorption is not linear. Studies by Moretti and colleagues (2015) and Stoffel and colleagues (2017) show that higher doses raise hepcidin and reduce the fraction absorbed, which means 60 mg in a single dose does not deliver double what 30 mg does. Smaller doses, taken less often, can therefore improve both absorption and tolerability.

Duration

Hemoglobin often begins to rise within two to four weeks, but replenishing stores usually takes three months or more after hemoglobin normalizes. The total duration should be set by a clinician using repeat blood tests.

18. Timing and Use

With Food or Without

Iron is absorbed best on an empty stomach, but taking it that way increases nausea in some people. Taking iron with a small amount of food that does not contain strong inhibitors can improve comfort at the cost of somewhat lower absorption. For iron bisglycinate, which resists some inhibitors, taking it with a light meal is a reasonable compromise for people who experience stomach upset.

Daily or Alternate-Day

Because hepcidin rises after each dose, taking iron on alternate days can increase fractional absorption. Stoffel and colleagues (2017, 2020) showed in iron-depleted women that alternate-day dosing increased fractional iron absorption and gave similar or better total absorbed iron over time than daily dosing. These studies used ferrous sulfate, but the physiology should apply to other iron forms. Clinical trials comparing daily and alternate-day regimens on hemoglobin and symptoms continue to emerge, and recommendations vary.

Time of Day

Morning dosing may be slightly better than evening dosing because hepcidin follows a daily rhythm, with higher levels later in the day. Split doses across the day are not advised, since a second dose within 24 hours tends to be poorly absorbed.

Helpful Pairings

•       Take with vitamin C, such as 50 to 100 mg or a vitamin C-containing food or drink, to improve non-heme iron absorption.

•       Take with a small meal if stomach upset occurs.

What to Separate From Iron

•       Tea, coffee and cocoa: separate by at least one to two hours.

•       Calcium supplements, dairy and antacids: separate by about two hours.

•       Zinc, magnesium and other mineral supplements: separate when possible.

•       Levothyroxine, certain antibiotics and other drugs listed in Section 21: follow separation intervals.

Monitoring

After starting treatment, clinicians typically recheck hemoglobin after about four weeks and ferritin after about two to three months. If there is no response, possible causes include nonadherence, ongoing blood loss, malabsorption (celiac disease, Helicobacter pylori infection, bariatric surgery), inflammation, or an incorrect diagnosis.

Practical Tips

•       Dark green or black stools are expected and harmless.

•       Constipation can be managed with fluids, fiber and, if needed, a stool softener recommended by a clinician.

•       If a dose is missed, skip it rather than doubling up.

•       Store in the original container, out of reach of children.

19. Available Forms

Form	Typical features	Considerations
Capsules	Most common; 18 to 30 mg elemental iron per capsule is typical	Easy to swallow; good for flexible dosing
Tablets	Often coated; sometimes combined with vitamin C	Coating masks taste; may dissolve more slowly
Powders and sachets	Flexible dosing; can be mixed into drinks	Taste and stability depend on formulation
Liquid drops and syrups	Used for infants, children and those who cannot swallow pills	Risk of dosing errors and tooth staining; use the supplied device
Gummies and chewables	Convenient; usually lower iron doses	Iron stability and taste are challenging; check elemental iron per serving
Prenatal multivitamins	Often contain 18 to 30 mg iron plus folate and other nutrients	Check for calcium or other minerals that may compete with iron
Fortified foods and beverages	Dairy, cereals, bars, drink mixes	Dose is small and variable; useful as a supplement to diet, not as treatment
Micronutrient powders ('sprinkles')	Single-dose sachets added to food	Mainly used in public health programs
Combination iron products	Iron with vitamin C, B12, folate, copper	Useful for convenience; confirm that doses match your needs

 

When comparing products, look at the elemental iron per serving, the servings per day, the other ingredients and whether the iron source is a true chelate. Extended-release or "buffered" claims have not been shown to offer a major absorption advantage and can reduce absorption by delivering iron beyond the duodenum.

20. Safety and Side Effects

General Safety Profile

At appropriate doses and in people who need iron, iron bisglycinate has a favorable safety record. The principal risks are gastrointestinal effects, harm from iron excess and acute overdose in children.

Common Side Effects

•       Nausea, stomach discomfort and abdominal pain, usually milder than with ferrous sulfate.

•       Constipation, and less commonly diarrhea.

•       Dark or black stools, which are expected and harmless.

•       Metallic taste, which is less common with the chelate.

•       Temporary tooth staining with liquid forms.

Serious Risks

Acute iron poisoning. Iron overdose is a leading cause of fatal poisoning in children under six in the United States. Toxicity can occur at elemental iron doses of about 20 mg per kg of body weight, and doses above about 60 mg per kg can be life-threatening. Symptoms include vomiting, bloody diarrhea, drowsiness, shock and liver injury. Anyone who suspects an overdose should seek emergency help immediately. In the United States, the FDA requires a warning on iron-containing supplements about accidental overdose in children under six.

Iron overload. People with hereditary hemochromatosis, thalassemia major, repeated transfusions or other iron-loading conditions should not take iron unless directed by a specialist. Chronic excess iron can contribute to organ damage in susceptible people, which is why a tolerable upper intake level of 45 mg per day exists for adults.

Infection and malaria. In a large trial in Pemba, Tanzania, routine iron and folic acid supplementation in preschool children in a high-malaria-transmission setting increased the risk of serious adverse events, including hospitalization and death, among children who were not iron deficient (Sazawal et al., 2006). The lesson is to target iron to those who need it and to follow local guidance in malaria-endemic regions.

Masking underlying disease. Iron deficiency in adults, especially men and postmenopausal women, can signal gastrointestinal blood loss. Treating the anemia without investigating its cause may delay the diagnosis of serious conditions.

Who Should Avoid It or Seek Advice First

•       People with hemochromatosis, iron overload or hemoglobinopathies without proven iron deficiency.

•       People with active gastrointestinal inflammation or obstruction, unless advised by a clinician.

•       Anyone taking interacting medicines (see Section 21).

•       Anyone with elevated or normal ferritin and no clinical need.

Allergies and Excipients

Allergic reactions to the iron chelate itself are rare. Reactions are more likely to involve excipients, flavors or colors, so people with allergies should check the full ingredient list.

21. Drug / Supplement Interactions

Iron interacts with many medicines and nutrients, mostly by binding in the gut and reducing absorption of either the drug or the iron. The table summarizes the main interactions. It is not exhaustive, and pharmacists can provide patient-specific advice.

Drug or supplement	Interaction	Practical guidance
Levothyroxine	Iron binds the drug and lowers its absorption	Separate by at least 4 hours; monitor thyroid tests
Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin)	Chelation reduces antibiotic absorption	Take the antibiotic at least 2 hours before or 6 hours after iron, or follow the label
Tetracyclines (doxycycline, minocycline)	Mutual reduction in absorption	Separate by 2 to 3 hours
Integrase inhibitors for HIV (dolutegravir, bictegravir, raltegravir)	Polyvalent cations reduce drug levels	Follow product-specific timing, often with food or separated by several hours
Levodopa and carbidopa	Iron reduces levodopa absorption	Separate doses and monitor symptoms
Methyldopa	Reduced absorption	Separate doses
Penicillamine	Reduced drug absorption	Separate by at least 2 hours
Bisphosphonates (alendronate, risedronate)	Reduced bisphosphonate absorption	Take the bisphosphonate first, on an empty stomach, and delay iron
Mycophenolate mofetil	May reduce drug exposure	Discuss timing with the prescriber
Proton pump inhibitors, H2 blockers, antacids	Lower stomach acid reduces iron salt absorption; antacids bind iron	Separate antacids by about 2 hours; discuss long-term acid suppression with a clinician
Calcium	Competes with iron absorption	Separate by about 2 hours
Zinc and magnesium	Compete at high doses	Separate when possible
Copper	Iron and copper balance each other; long-term high iron can affect copper status	Ensure adequate copper intake
Vitamin C	Enhances absorption	Helpful pairing
Tea, coffee, cocoa, red wine	Polyphenols reduce absorption	Separate by 1 to 2 hours
Other iron-containing products	Additive iron load	Count all sources toward the upper limit

 

22. Special Populations

Pregnancy and Lactation

Iron needs rise substantially during pregnancy to support expanded blood volume, the placenta and the fetus. The WHO recommends daily oral iron with folic acid for pregnant women, typically 30 to 60 mg of elemental iron. Iron bisglycinate is commonly used because of its tolerability, and trial evidence supports lower doses than ferrous sulfate. Dosing should be guided by blood tests and a clinician. Iron needs fall during lactation, particularly if menstruation has not resumed.

Infants and Children

Infants, especially preterm or exclusively breastfed infants after about four to six months, and toddlers have high iron needs. Iron should be given in measured, age-appropriate doses under pediatric supervision. Overdose risk is high, and adult products must be kept away from children.

Adolescents

Rapid growth and the onset of menstruation raise iron requirements in adolescent girls. Screening for iron deficiency is reasonable in at-risk adolescents, and supplementation should be matched to test results.

Older Adults

Iron deficiency in older adults is often due to occult blood loss, poor diet or inflammation, and it should be investigated. Inflammation raises hepcidin and can make oral iron less effective. Constipation can be a particular problem, and the tolerability advantage of the chelate may be useful.

Vegetarians and Vegans

Plant-based diets provide only non-heme iron, and phytates and polyphenols lower its absorption. Iron-rich foods, vitamin C pairing, soaking and fermenting grains and legumes, and fortified foods all help. Supplements are appropriate when blood tests show deficiency.

Athletes

Endurance athletes can lose iron through sweat, gastrointestinal bleeding, foot-strike hemolysis and heavy training-related hepcidin elevation. Supplementation is helpful when deficiency is confirmed. Iron in athletes without deficiency has not been shown to improve performance.

Heavy Menstrual Bleeding

Heavy periods are among the most common causes of iron deficiency in women. Treating the cause, together with iron replacement, offers the best outcome.

Gastrointestinal and Absorptive Conditions

Celiac disease, inflammatory bowel disease, Helicobacter pylori infection, atrophic gastritis and bariatric surgery can all reduce iron absorption. Oral iron may be less effective, and intravenous iron is often needed. In active inflammatory bowel disease, some clinicians prefer intravenous therapy because oral iron may aggravate symptoms.

Chronic Kidney Disease and Heart Failure

Iron deficiency is common in both conditions. Oral iron is often poorly effective in heart failure, and intravenous iron has stronger evidence in guidelines. These patients should be managed by a specialist.

Iron Overload Conditions

Hereditary hemochromatosis, thalassemia and other iron-loading conditions are contraindications to iron supplementation unless deficiency is proven. Men and postmenopausal women should generally avoid unsupervised iron supplements because their iron needs are low and deficiency is less common.

23. Quality, Testing and Authentication

What Good Testing Covers

•       Identity: infrared spectroscopy (FTIR) or similar methods to confirm that the material is iron bisglycinate rather than a blend.

•       Assay: elemental iron by ICP-OES, ICP-MS or titration, to confirm the label claim.

•       Ferrous versus ferric content: to verify that iron is in the ferrous state.

•       Chelation percentage: to confirm that iron is bound as chelate rather than present as free salt.

•       Glycine content: to confirm the ligand ratio.

•       Heavy metals: lead, arsenic, cadmium and mercury, using ICP-MS and following pharmacopeial limits such as USP <2232> or equivalent standards.

•       Microbiology: total plate count, yeasts and molds, and absence of pathogens.

•       Physical tests: moisture, particle size, dissolution or disintegration for finished products.

•       Stability: accelerated and real-time testing for iron assay and ferrous fraction.

Third-Party Verification

Independent certification programs, such as USP Verified, NSF, Informed Choice and similar schemes, test finished supplements for label accuracy and contaminants. These marks are valuable signals but are not universal, and they do not guarantee clinical benefit.

Reading a Certificate of Analysis

For brands and professionals, a certificate of analysis should list the batch number, test methods, results and limits, laboratory identity and date. It should include iron assay, chelation or ferrous content, and contaminants. A certificate that gives only a general statement of "meets specification" is insufficient.

Consumer Checklist

•       Is elemental iron clearly listed per serving?

•       Is the source named as ferrous bisglycinate or iron bisglycinate chelate?

•       Is there a third-party testing mark or a published batch test?

•       Are other ingredients that could interfere with iron, such as large calcium doses, listed?

•       Does the packaging carry the child-safety warning and an expiry date?

24. Adulteration and Contamination Risks

Heavy Metals

Because iron sources can come from industrial processes, heavy metals are the most important contaminant concern. Lead and arsenic are of particular concern for products used by children and pregnant women. Reputable suppliers test every lot.

Mixtures Labeled as Chelates

A recognized quality risk in mineral supplements is the substitution of cheaper physical blends, such as ferrous sulfate mixed with glycine, for a true chelate. Such blends do not necessarily share the properties of the chelate. Analytical methods that confirm chelation can detect this, but routine retail products are rarely tested.

Oxidized or Degraded Iron

Poor storage or manufacturing can produce excess ferric iron, causing brown discoloration, reduced potency and altered absorption. Moisture-protective packaging and desiccants are common safeguards.

Incorrect Potency

Products may under- or over-deliver elemental iron. Over-delivery is a safety issue, and under-delivery undermines treatment. Label claims are sometimes confused when a manufacturer lists the compound weight instead of elemental iron.

Cross-Contamination and Excipients

Shared equipment can lead to cross-contact with allergens. Fillers, colors and flavors can introduce additional risks, especially in gummies and liquids for children.

Counterfeits and Unregulated Sales

Online marketplaces can host products with unverified provenance. Buying from established brands and pharmacies and checking batch numbers reduces risk.

Red Flags

•       Claims of "ten times" absorption or "no side effects."

•       No elemental iron amount on the label.

•       No lot number or expiry date.

•       Proprietary blends that hide the amount of iron.

•       Extremely high iron doses per serving, particularly in products suited to children.

25. Regulatory Overview

Regulatory status varies by country, and rules change. The following is a general overview and should be verified against current official sources before use in labeling or marketing.

United States

Iron bisglycinate is marketed as a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) and as a food fortificant under GRAS (generally recognized as safe) principles. Supplements containing iron must carry the warning statement about accidental overdose in children under six, required by FDA regulation 21 CFR 101.17(e), and iron-containing products are subject to unit-dose packaging requirements under 21 CFR 310.518. Supplements may carry structure-function claims, such as supporting healthy iron levels, but may not claim to treat or cure iron deficiency anemia.

European Union

Ferrous bisglycinate is a permitted source of iron for food supplements under Directive 2002/46/EC and for food fortification under Regulation (EC) No 1925/2006. The European Food Safety Authority (EFSA) has evaluated ferrous bisglycinate as a source of iron. Authorized health claims for iron, such as contributing to normal formation of red blood cells and hemoglobin and to the reduction of tiredness and fatigue, are listed in Regulation (EU) No 432/2012 and can be used when the product meets the conditions of use.

Other Jurisdictions

•       Canada: iron supplements are regulated as natural health products, and monographs set dose and labeling conditions.

•       Australia and New Zealand: iron supplements fall under therapeutic goods rules, and food fortification is governed by food standards.

•       India: the Food Safety and Standards Authority of India (FSSAI) regulates nutraceuticals and fortification, and ferrous bisglycinate is among the iron compounds addressed in its fortification and nutraceutical frameworks. Check current regulations for each use case.

•       International: Codex Alimentarius and WHO provide guidance on nutrient reference values and fortification.

Claims and Marketing

Across markets, claims must be truthful, supported by evidence and consistent with the product's regulatory category. Superiority claims over other iron forms should be backed by comparative evidence, and disease treatment claims are generally restricted to approved medicines.

26. Research Gaps

•       Independent head-to-head trials. More large, double-blind, independently funded randomized trials comparing iron bisglycinate with ferrous sulfate and other forms are needed in non-pregnant adults, children and special populations.

•       Clinical outcomes beyond hemoglobin. Few studies measure fatigue, cognition, quality of life, restless legs symptoms or pregnancy and birth outcomes.

•       Dose optimization. The best combination of dose, frequency and timing for the chelate, including alternate-day regimens, is not well defined.

•       Mechanism. The extent of intact chelate uptake and the exact transport pathways remain unclear.

•       Gut microbiome. Direct human data on how iron bisglycinate affects gut microbiota compared with other iron forms are limited.

•       Inflammation and chronic disease. Performance of oral iron bisglycinate in inflammatory bowel disease, kidney disease, heart failure and obesity needs more study.

•       Long-term safety. Data beyond several months of supplementation are limited, particularly in children.

•       Standardized product quality. Studies often use specific branded raw materials, and results may not apply to all commercial products.

•       Cost-effectiveness. Higher ingredient costs should be weighed against tolerability and adherence benefits.

27. Frequently Asked Questions

What is iron bisglycinate?

Iron bisglycinate is a form of iron in which one ferrous iron ion is bound to two glycine molecules. It is used in supplements and fortified foods to prevent and treat iron deficiency.

Is iron bisglycinate better absorbed than ferrous sulfate?

It is better absorbed in the presence of inhibitors such as phytate, and clinical trials show that lower doses can match higher doses of ferrous sulfate in pregnancy. In meals without inhibitors, absorption is similar.

Does it cause less constipation?

Many users and several trials report fewer gastrointestinal complaints, including constipation, but the effect is not universal. Hydration, fiber and appropriate dosing also matter.

Is iron bisglycinate the same as iron glycinate?

The terms are often used interchangeably, but "iron glycinate" can also describe less well-defined products. Look for "ferrous bisglycinate chelate" and quality documentation.

How much should I take?

The right dose depends on your age, sex, iron status and medical conditions. Studies in adults use about 15 to 60 mg of elemental iron per day, and the upper limit for adults is 45 mg per day without medical supervision. Ask a clinician and use blood tests.

Should I take it on an empty stomach?

Absorption is best on an empty stomach, but a light meal can reduce nausea. Avoid tea, coffee, calcium and antacids around the dose.

Can I take it every day?

Daily dosing is standard, and alternate-day dosing may improve absorption and tolerability for some people. Discuss options with a clinician.

How long until I feel better?

Energy and symptoms may improve within a few weeks, hemoglobin often rises within two to four weeks, and ferritin takes several months to rebuild.

Is it safe in pregnancy?

Yes, it is widely used in pregnancy at recommended doses and is supported by randomized trial evidence. Doses should be guided by a clinician and blood tests.

Can children take it?

Only under pediatric guidance, using age-appropriate products and doses. Iron overdose is dangerous in young children, and all iron products must be stored out of reach.

Can I take it with vitamin C?

Yes. Vitamin C improves non-heme iron absorption and is a common and sensible pairing.

Who should not take iron bisglycinate?

People with hemochromatosis or iron overload, and people without a need for iron, should avoid it. Others should check for drug interactions first.

Does it turn stools dark?

Yes, dark green or black stools are normal. Tarry, sticky stools with abdominal pain, or any red blood, need medical evaluation.

How do I choose a good product?

Choose a product that lists elemental iron, names ferrous bisglycinate chelate, has third-party testing and fits your dosing plan.

28. Scientific References

References were compiled for educational purposes. Readers should verify details against the original publications and current guidelines.

1.      Allen LH. Iron supplements: scientific issues concerning efficacy and implications for research and programs. J Nutr. 2002;132(4 Suppl):813S-819S.

2.      Bovell-Benjamin AC, Viteri FE, Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000;71(6):1563-1572.

3.      Duque X, Martinez H, Vilchis-Gil J, et al. Effect of supplementation with ferrous sulfate or iron bis-glycinate chelate on ferritin concentration in Mexican schoolchildren: a randomized controlled trial. Nutr J. 2014;13:71.

4.      Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023;81(8):904-920.

5.      Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435-443.

6.      Houston BL, Hurrie D, Graham J, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open. 2018;8(4):e019240.

7.      Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academies Press; 2001.

8.      Jaeggi T, Kortman GAM, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731-742.

9.      Jeppsen RB, Borzelleca JF. Safety evaluation of ferrous bisglycinate chelate. Food Chem Toxicol. 1999;37(7):723-731.

10.   Layrisse M, Garcia-Casal MN, Solano L, et al. Iron bioavailability in humans from breakfasts enriched with iron bis-glycine chelate, phytates and polyphenols. J Nutr. 2000;130(9):2195-2199.

11.   Milman N, Jonsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42(2):197-206.

12.   Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126(17):1981-1989.

13.   National Institutes of Health, Office of Dietary Supplements. Iron: Fact Sheet for Health Professionals. Updated edition available at ods.od.nih.gov.

14.   Olivares M, Pizarro F, Pineda O, et al. Milk inhibits and ascorbic acid favors ferrous bis-glycine chelate bioavailability in humans. J Nutr. 1997;127(7):1407-1411.

15.   Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381-384.

16.   Pizarro F, Olivares M, Uauy R, et al. Iron bis-glycine chelate competes for the nonheme-iron absorption pathway. Am J Clin Nutr. 2002;76(3):577-581.

17.   Pena-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;(7):CD004736.

18.   Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet. 2006;367(9505):133-143.

19.   Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524-e533.

20.   Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020;105(5):1232-1239.

21.   Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117383.

22.   World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: WHO; 2016.

23.   World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: WHO; 2020.

24.   World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: WHO; 2011.

25.   Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other substances to foods; Directive 2002/46/EC on food supplements; Regulation (EU) No 432/2012 on permitted health claims.

26.   U.S. Code of Federal Regulations, 21 CFR 101.17(e) and 21 CFR 310.518 (iron-containing supplements; labeling and packaging).

29. Related Content / Product Bridge

Where This Guide Fits

This pillar page is the central scientific reference for iron bisglycinate. Supporting articles can explore specific questions in depth and link back here for the full evidence base.

Suggested Supporting Articles

•       Iron Bisglycinate vs Ferrous Sulfate: Which Is Better Tolerated?

•       Iron Bisglycinate in Pregnancy: Dosage, Safety and Evidence

•       Signs and Symptoms of Iron Deficiency and When to Test Ferritin

•       How to Take Iron Supplements for Best Absorption

•       Alternate-Day Iron Dosing Explained

•       Iron Supplement Interactions: Medications to Separate From Iron

•       Best Iron Sources for Vegetarians and Vegans

•       Iron for Children: Safe Dosing and Overdose Prevention

•       Iron Glycinate vs Iron Bisglycinate: Label Reading Guide

•       How to Choose a High-Quality Iron Supplement

Product Bridge

Readers who have confirmed iron deficiency, with a clinician's input, may be looking for a supplement that uses a true ferrous bisglycinate chelate with clear elemental iron labeling, third-party testing and a dose appropriate for their needs. Product pages should state the elemental iron per serving, identify the chelate source, publish batch testing for identity, potency and heavy metals, include the child-safety warning and avoid disease treatment claims.

Suggested call to action (placeholder): "Explore our iron bisglycinate options and review our testing documentation." Add your product links, certificates of analysis and dosage guide here.

Important Notice

This article is for educational purposes and is not medical advice. Iron supplements should be used based on blood test results and professional guidance. Keep all iron products out of reach of children, and seek emergency care immediately in case of overdose.